CN110684036A - Method for preparing eribulin mesylate - Google Patents
Method for preparing eribulin mesylate Download PDFInfo
- Publication number
- CN110684036A CN110684036A CN201911152952.4A CN201911152952A CN110684036A CN 110684036 A CN110684036 A CN 110684036A CN 201911152952 A CN201911152952 A CN 201911152952A CN 110684036 A CN110684036 A CN 110684036A
- Authority
- CN
- China
- Prior art keywords
- erbl
- formula
- eribulin mesylate
- reaction
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to a preparation method of eribulin mesylate. The reaction involves reacting 2- [ (2S) -2-benzoyloxy ] -3- [ (2R,3R,3aS,7R,10S,11S,12S,13R,14S,15S,16E,21S,24S,27S,29R,31R,32aS) -12,13, 15-tris [ [ (1, 1-dimethylethyl) dimethylsilyl ] oxy ] -3,3a,4,5,6,7,8,9,10,11,12,13,14,15,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,32 a-triacontahydro-3-methoxy-29-methyl-23, 30-bis (methylene) -5, 18-dioxy-7, 11:10,14:21,24:27, 31-tetracyclooxy-2H-cyclotriundec [ b ] furan-2-yl ] propane The group ] -1H-phthalimide (N-ERBL-05) is used as an intermediate, and the eribulin mesylate is prepared through three steps of reactions.
Description
Technical Field
The invention belongs to the field of chemical synthesis, and particularly relates to preparation of a crude drug complex natural modified drug eribulin mesylate.
Background
Halichondrin B is a poly (poly) ether macrolide isolated from the scarce Japanese sponge Halichondriaokadai by Japanese scientist Uemura et al in the last 80 th century, and although halichondrin B only contains three elements of C \ H \ O, the compound structure is quite complex. Further research finds that the halichondrin B has very strong inhibiting effect on cancer cells in and out of a mouse body in a mouse experiment. Further research by chemists has also revealed that common sponges, such as the Phakellia, Lissodendory and Axinella families, also contain halichondrin B. The systematic activity evaluation of halichondrin B in 60 cancer cell lines by the national institute of tumor in the united states has demonstrated that halichondrin B acts in a similar mechanism to known anti-tubulin drugs in anti-cancer cell proliferation, but in a different biochemical mechanism. The halichondrin B has strong activity and unique action mechanism, so that the halichondrin B has attracted the attention of academia and the industry. However, since nature has a limit in the amount of sample extracted and separated from the sponge, development has been slow. To this end, the preparation of halichondrin B and its analogs by means of chemical synthesis has attracted extensive interest to chemists.
Halichondrin B has the following structure:
professor Kishi, Harvard university, systematically studied the total synthesis of halichondrin B and its analogs. A great deal of research has found that the lactone segment on the right of halichondrin B as shown above is a more anticancer active carrier than the polyether segment on the left, because the segment on the right contains various functional groups, and the structure of the polyether segment is monotonous. These studies have further prompted synthetic chemists to prepare a series of halichondrin B analogs for activity testing. Eribulin mesylate is one of halichondrin B analogs, eventually approved by the FDA in the united states for the treatment of metastatic breast cancer in 2010 through phase III clinical trials under the trade name HALAVENTM. The chemical structure of eribulin mesylate contains 19 chiral centers, and the chemical structural formula is as follows:
to date, a large number of patents and literature reports have been published on the preparation of eribulin mesylate. However, many documents refer to the final conversion of both hydroxyl groups of the compound to terminal amino alcohols (ERBL-07 → eribulin mesylate), and the reaction mechanism of such synthetic strategies involves the formation of an oxatricyclic intermediate (intermediate 1 and intermediate 2) followed by the opening of the amino ring. Since the ring opening of the amino group of the terminal oxatricyclic ring inevitably produces isomer impurities (isomer-1, isomer-2, isomer-3) which are similar to the product structure and are very difficult to remove in the finished product, it is crucial to develop a new synthetic strategy for successfully avoiding the production of the amino isomer impurities. The conventional synthetic route to convert the terminal dihydroxy group to an amino alcohol and some isomeric impurity structures are as follows:
disclosure of Invention
The invention aims to provide a novel method for preparing eribulin mesylate, aiming at avoiding the defect that a traditional synthetic route is easy to cause a large amount of isomer impurities.
The synthetic route of the invention is as follows:
the first step of the reaction involves the oxidation of two hydroxyl groups in the structure of N-ERBL-01 (one hydroxyl group is oxidized into a ketone carbonyl group, and the other hydroxyl group is oxidized into an aldehyde group) by using N-ERBL-01 as a starting material under the oxidation condition to obtain an N-ERBL-02 intermediate.
The oxidant used in the first step of the reaction is Dess-Martin oxidant, and the reaction solvent is dichloromethane.
The second step of the reaction involves the reaction of the N-ERBL-02 intermediate in SmI2Removing the protecting group of p-toluenesulfonyl (Ts) under the action of the N-ERBL-03 intermediate.
The third step of the reaction involves the reaction of the N-ERBL-03 intermediate in CrCl2/NiCl2In the presence of the N-ERBL-04 intermediate, the terminal alkenyl iodine reacts with aldehyde groups in molecules to prepare the N-ERBL-04 intermediate. The solvents used for this step include acetonitrile and THF.
The fourth reaction step involves the oxidation of hydroxyl to carbonyl of the N-ERBL-04 intermediate under the oxidation condition to prepare the (2- [ (2S) -2-benzoyloxy) N-ERBL-05 intermediate]-3-[(2R,3R,3aS,7R,10S,11S,12S,13R,14S,15S,16E,21S,24S,27S,29R,31R,32aS)-12,13,15-
[ [ (1, 1-Dimethylethyl) dimethylsilyl group]Oxygen gas]-3,3a,4,5,6,7,8,9,10,11,12,13,14,15,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,32 a-triacontahydro-3-methoxy-29-methyl-23, 30-bis (methylene) -5, 18-dioxy-7, 11:10,14:21,24:27, 31-tetracyclooxy-2H-cyclohentriacontane [ b]Furan-2-yl]Propyl radical]-1H-phthalimide). The oxidation reaction used in this step is Dess-Martin oxidation or Swern oxidation.
The fifth reaction step involves reacting the N-ERBL-05 intermediate in the presence of TBAF to produce the N-ERBL-06 intermediate (1R,2S,3S,4S,5S,6R,11S,14S,17S,19R,21R,23S,25R,26R,27S,31R,34S) -25- [ (2S) -3-phthalimido-2-benzoyloxypropyl ] -2, 5-dihydroxy-26-methoxy-19-methyl-13, 20-dimethylene-24, 35,36,37,38, 39-hexaoxaheptacyclo [29.3.1.13,6.14,34.111,14.117,21.023,27] nonadecane-8, 29-dione).
The sixth reaction step involves reacting the N-ERBL-06 intermediate in the presence of PPTS (pyridine p-toluenesulfonate) to prepare the N-ERBL-07 intermediate (2R,3R,3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS) -2- [ (2S) -3-phthalimide-2-benzoyloxypropyl ] -3-methoxy-26-methyl-20, 27-dimethylene hexadecahydro-11, 15:18,21:24, 28-triepoxy-7, 9-ethano-12, 15-methano-9H, 15H-furo [3,2-i ] furo [2',3', 5,6] pyran [4,3-b ] [1,4] dioxocyclopentadecanyl-5 (4H) -one).
And the seventh step of the reaction involves removing the phthalimide protecting group and the benzoyl protecting group of the N-ERBL-07 intermediate under the ammonia water condition, and then adding methanesulfonic acid to prepare eribulin mesylate.
Detailed Description
The following exemplary embodiments are provided to illustrate the present invention, and simple replacement and modification of the present invention by those skilled in the art are within the technical scheme of the present invention.
EXAMPLE I preparation of N-ERBL-02 intermediate
Into a four-necked flask was added N-ERBL-01 intermediate (25.00g,15.37mmol) and CH2Cl2(500mL), after stirring the supernatant, Dess-Martin oxidant (10g,23.58mmol) was added in portions. After the addition was complete, the system was stirred at room temperature to TLC to monitor the completion of the reaction of the starting material. After the reaction was complete, the system was quenched by addition of saturated aqueous sodium bicarbonate (500 mL). The system was allowed to stand and the organic phase was separated. The organic phase was stripped of organic solvent under reduced pressure at low temperature and the residue was purified by column chromatography to give N-ERBL-02 intermediate (20.23g, 81.1%).
EXAMPLE two preparation of N-ERBL-03 intermediate
Sm (13.05g,86.79mmol) was added to a four-necked bottleAnd THF (500mL) was added to the reaction mixture under stirring, and after the addition was complete, the mixture was stirred at room temperature for 5 hours. In another four-necked flask, N-ERBL-02 intermediate (15.05g,9.34mmol), methanol (200mL) and THF (500mL) were added, the system was cooled to-85 ℃ with stirring, and then the previously prepared Smi was added dropwise2And (3) solution. After the dropwise addition, the system was stirred for 4 hours until TLC confirmed that the reaction of the starting materials was complete. Adding saturated K at low temperature2CO3Aqueous solution (200mL) was quenched. TBME (1L) was added after the system was warmed to room temperature, stirred for 2 hours, and allowed to stand to separate an organic phase. The organic phase was removed under reduced pressure and the residue was purified by column chromatography to give N-ERBL-03 intermediate (10.51g, 76.7%).
EXAMPLE III preparation of N-ERBL-04 intermediate
Acetonitrile (550mL) and CrCl are added into a four-mouth bottle2(26.0g,211.55mmol) and ligand (CAS:480444-15-3,63.2g,213.24 mmol). After the addition was complete triethylamine (21.5g,212.5mmol) was slowly added dropwise with stirring. After the addition is finished, stirring for 2 hours at the temperature of 30-35 ℃, and then adding NiCl2(2.75g,21.1mmol) and stirred. A solution of the N-ERBL-03 intermediate (22.5g,15.33mmol) in THF (500mL) was then added dropwise to the reaction at room temperature. After the dropwise addition, the system is stirred for 5 hours at room temperature until the controlled raw material reaction in TLC is finished. The reaction was quenched by addition of water (300mL), the system was filtered, the filtrate was extracted three times with N-heptane, the organic phases were combined, the organic phase was removed under reduced pressure to remove the organic solvent, and the residue was purified by column chromatography to give N-ERBL-04 intermediate (15.26g, 75.0%).
EXAMPLE four N-ERBL-05 intermediate (2- [ (2S) -2-benzoyloxy]-3-[(2R,3R,3aS,7R,10S,11S,12S,13R,14S,15S,16E,21S,24S,27S,29R,31R,32aS)-12,13,15-
[ [ (1, 1-Dimethylethyl) dimethylsilyl group]Oxygen gas]-3,3a,4,5,6,7,8,9,10,11,12,13,14,15,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,32 a-triacontahydro-3-methoxy-29-methyl-23, 30-bis (methylene) -5, 18-dioxy-7, 11:10,14:21,24:27, 31-tetracyclooxy-2H-cyclohentriacontane [ b]Furan-2-yl]Propyl radical]-1H-phthalimide) preparation
N-ERBL-04 intermediate (11.80g,8.89mmol) and dichloromethane (150mL) were added to a four-necked flask, stirred to dissolve, and Dess-Martin oxidant (10.75g,25.35mmol) was added in portions at room temperature. And stirring the system for 2 hours after the addition is finished until the reaction of the raw materials in the TLC is finished. The system was quenched by addition of saturated aqueous sodium bicarbonate (300 mL). The system was allowed to stand and the organic phase was separated. The organic phase was stripped of organic solvent at low temperature under reduced pressure and the residue was purified by column chromatography to give N-ERBL-05 intermediate (10.66g, 90.5%).
EXAMPLE V preparation of N-ERBL-06 intermediate (1R,2S,3S,4S,5S,6R,11S,14S,17S,19R,21R,23S,25R,26R,27S,31R,34S) -25- [ (2S) -3-phthalimido-2-benzoyloxypropyl ] -2, 5-dihydroxy-26-methoxy-19-methyl-13, 20-dimethylene-24, 35,36,37,38, 39-hexaoxaheptacyclo [29.3.1.13,6.14,34.111,14.117,21.023,27] nonadecane-8, 29-dione)
N-ERBL-05 intermediate (7.1g,5.36mmol) and THF (115mL) were added to a three-necked flask, and after stirring, imidazole (1.85g,27.18mmol) and TBAF (1M in THF,11mL) were added to the system. After the addition is finished, the system reacts at room temperature until the raw materials are completely reacted in TLC. Methanol (50mL) and 30g of resin were added, stirred for 2 hours, filtered, the filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography to give N-ERBL-06 intermediate (4.57g, 85.5%).
Example six: N-ERBL-07 intermediate (2R, 3aS,7R,8aS,9S,10aR,11S,12R,13aR,13bS,15S,18S,21S,24S,26R,28R,29aS) -2- [ (2S) -3-phthalimide-2-benzoyloxypropyl ] -3-methoxy-26-methyl-20, 27-dimethylenehexadecahydro-11, 15:18,21:24, 28-triepoxy-7, 9-ethano-12, 15-methano-9H, 15H-furo [3,2-i ] furo [2',3': preparation of 5,6] pyran [4,3-b ] [1,4] dioxopentacosan-5 (4H) -one).
N-ERBL-06 intermediate (4.0g,4.01mmol) and methylene chloride (100mL) were added to a three-necked flask, and PPTS (5.6g,22.3mmol) was added to the reaction system at room temperature after dissolution with stirring. The system was stirred at room temperature for 2 hours and the TLC medium control material reaction was complete. The reaction solution was subjected to solvent removal under reduced pressure at a temperature of not higher than 15 ℃ and the residue was purified by column chromatography to give N-ERBL-07 intermediate (3.22g, 81.9%).
EXAMPLE seventhly preparation of eribulin mesylate
A three-necked flask was charged with N-ERBL-07 intermediate (2.5g,2.55mmol), isopropanol (150mL), and ammonia (250 mL). After the addition, the system was stirred at a temperature of not higher than 15 ℃ for 36 hours. TLC (thin layer chromatography) is adopted to control the raw material to completely react, the reaction solution is concentrated under reduced pressure at the temperature of not higher than 15 ℃, the residue is purified by column chromatography, the obtained free base is dissolved in acetonitrile (30mL), methanesulfonic acid (250mg) is added under stirring, the system is stirred for 10 minutes, and then the solvent is removed from the system under high vacuum at the temperature of not higher than 15 ℃ to obtain eribulin mesylate (2.06g, 95.9%).
Claims (4)
1. A process for preparing eribulin mesylate having the formula:
2. a process for the preparation of a compound of formula N-ERBL-06 having the formula as shown in claim 1, characterized in that a compound of formula N-ERBL-05 is reacted in the presence of TBAF to give a compound of formula N-ERBL-06.
3. A process for the preparation of a compound of formula N-ERBL-07 according to claim 1, characterized in that a compound of formula N-ERBL-06 is reacted in the presence of PPTS (pyridine p-toluenesulfonate) to give a compound of formula N-ERBL-07.
4. The preparation method of eribulin mesylate as shown in claim 1, wherein the compound of formula N-ERBL-07 is subjected to simultaneous removal of phthalimide protecting group and benzoyl protecting group under ammonia condition, and then methanesulfonic acid is added to prepare eribulin mesylate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911152952.4A CN110684036B (en) | 2019-11-22 | 2019-11-22 | Method for preparing eribulin mesylate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911152952.4A CN110684036B (en) | 2019-11-22 | 2019-11-22 | Method for preparing eribulin mesylate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110684036A true CN110684036A (en) | 2020-01-14 |
| CN110684036B CN110684036B (en) | 2022-04-12 |
Family
ID=69117343
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911152952.4A Active CN110684036B (en) | 2019-11-22 | 2019-11-22 | Method for preparing eribulin mesylate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110684036B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016031796A1 (en) * | 2014-08-27 | 2016-03-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Method for producing antitumor agent using homogenizer |
| CN105683198A (en) * | 2013-11-04 | 2016-06-15 | 卫材R&D管理有限公司 | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b |
| US20180009825A1 (en) * | 2016-07-06 | 2018-01-11 | Apicore Us Llc | Methods of making eribulin mesylate |
| CN108997267A (en) * | 2004-06-03 | 2018-12-14 | 卫材R&D管理有限公司 | It is used to prepare the intermediate of the analog of halichondrin B |
| CN109694379A (en) * | 2017-10-24 | 2019-04-30 | 江苏恒瑞医药股份有限公司 | It is used to prepare the intermediate and preparation method thereof of eribulin |
-
2019
- 2019-11-22 CN CN201911152952.4A patent/CN110684036B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108997267A (en) * | 2004-06-03 | 2018-12-14 | 卫材R&D管理有限公司 | It is used to prepare the intermediate of the analog of halichondrin B |
| CN105683198A (en) * | 2013-11-04 | 2016-06-15 | 卫材R&D管理有限公司 | Macrocyclization reactions and intermediates useful in the synthesis of analogs of halichondrin b |
| WO2016031796A1 (en) * | 2014-08-27 | 2016-03-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Method for producing antitumor agent using homogenizer |
| US20180009825A1 (en) * | 2016-07-06 | 2018-01-11 | Apicore Us Llc | Methods of making eribulin mesylate |
| CN109694379A (en) * | 2017-10-24 | 2019-04-30 | 江苏恒瑞医药股份有限公司 | It is used to prepare the intermediate and preparation method thereof of eribulin |
Non-Patent Citations (1)
| Title |
|---|
| BRIAN C. AUSTAD ET AL.: "commercial Manufacture of Halaven:Chemoselective Transformations En Route to Structurally Complex Macrocyclic Ketones", 《SYNLETT》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN110684036B (en) | 2022-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112608296B (en) | Synthesis method of Brazilane natural product Brazilane | |
| KR20180053320A (en) | Process for the preparation of nucleoside phosphoramidate prodrugs and intermediates thereof | |
| CN111233795B (en) | Preparation method and application of chiral gamma-butyrolactone compound and derivative thereof | |
| JP2022107010A (en) | Bryostatin compounds and methods of preparing the same | |
| CN111138443B (en) | Preparation method for total synthesis of 4' -demethylepipodophyllotoxin | |
| TWI675842B (en) | Intermediates of eribulin and their preparation methods | |
| Pal et al. | Benzoxazole alkaloids: occurrence, chemistry, and biology | |
| CN110684036B (en) | Method for preparing eribulin mesylate | |
| CN110872317A (en) | Preparation method of antitumor drug molecule (+) -Preussin intermediate | |
| US9296774B2 (en) | Halogenated dideoxy sugar derivates, preparation method and application thereof | |
| WO2008022462A1 (en) | Para-quinol derivatives and methods of stereo selectively synthesizing and using same | |
| US6677456B2 (en) | Pentacyclic taxan compound | |
| CN115057839B (en) | Eucalyptus type sesquiterpene lactone compound and preparation and application thereof | |
| JPH10504533A (en) | Bioactive acetogenins and derivatives | |
| NZ225879A (en) | 3'-demethoxyepipodophyllotoxin glucoside derivatives and pharmaceutical compositions | |
| CN113354659B (en) | Synthesis of eribulin mesylate | |
| CN115073406A (en) | Eucalyptus alkane type sesquiterpene lactone TBA derivative and application thereof | |
| CN109369667B (en) | 2, 3, 6-trideoxyglycosyldemethylepipodophyllotoxin compound and preparation method and application thereof | |
| Tibhe et al. | Total synthesis of gabosine H and two non-natural gabosines | |
| Occhiato et al. | Enantioselective synthesis of indolizine derivatives by rearrangement-cyclization of isoxazoline-5-spirocyclopropanes | |
| CA2804031A1 (en) | Preparation of tesetaxel and related compounds and corresponding synthesis intermediate | |
| CN114380840B (en) | Synthesis of eribulin | |
| CN109503681B (en) | 2-Fluoro-L-ristosamine compound and synthetic method and application thereof | |
| CN103012330A (en) | Preparation method of taxol anticancer drugs XRP6258 | |
| WO2021249545A1 (en) | Method for one-step preparation of polyether having trans-fused polycyclic ether framework structure |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province Applicant after: Jiangsu Huiju Pharmaceutical Co.,Ltd. Address before: 226123 No. 18 Qinghua Road, three Factory Street, Haimen City, Nantong, Jiangsu Applicant before: WISDOM PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province Applicant after: Jiangsu Huiju Pharmaceutical Co.,Ltd. Address before: 226123 No.18, Qinghua Road, Sanchang street, Haimen District, Nantong City, Jiangsu Province Applicant before: Jiangsu Huiju Pharmaceutical Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |